What is Neurological Genetic Testing for Alzheimer’s?
Neurological genetic testing for Alzheimer’s is a specialized medical examination that assesses an individual’s genetic makeup to identify specific genetic variations associated with this neurological condition. It is worthwhile to mention that Alzheimer’s is sporadic and not genetic. Alzheimer’s affects the brain, spinal cord, nerves, and muscles. Neurological genetic testing involves analyzing an individual’s DNA to detect mutations or gene alterations that may contribute to the development of neurological disorders. This type of testing can provide valuable insights into Alzheimer’s and its underlying causes, aiding in accurate diagnosis, risk assessment, and personalized treatment planning. It is particularly beneficial for individuals with a family history of neurological disorders or those exhibiting unexplained symptoms. By uncovering genetic factors, neurological genetic testing contributes to a deeper understanding of these complex conditions and informs medical management decisions for affected individuals and their families.
In comparison, Neurogenetics is a specialized field of genetics that focuses on studying the genetic basis of neurological disorders and conditions that affect the nervous system. It involves investigating how genetic variations and mutations contribute to various neurological diseases’ development, progression, and inheritance. Neurogenetics encompasses a wide range of disorders, including neurodevelopmental disorders, neurodegenerative diseases, neuromuscular disorders, and more.
Genes Linked with Alzheimer’s
Genetic testing for Alzheimer’s disease aims to identify specific genetic variations that can increase the risk of developing the condition. There are several genes associated with Alzheimer’s disease, and genetic testing can provide information about an individual’s susceptibility to the disease. Researchers have developed a protocol for precise whole human genome sequencing using Oxford Nanopore technology, allowing for a thorough understanding of genome variation and methylation. The two main genes that are often tested for Alzheimer’s disease are:
- APOE gene: The APOE gene has different variants, with the ε4 allele being the most well-known genetic risk factor for late-onset Alzheimer’s disease. People who inherit one copy of the APOE ε4 allele have an increased risk of developing Alzheimer’s disease, while those with two copies have an even higher risk. However, it’s important to note that not everyone with the APOE ε4 allele will develop Alzheimer’s, and not everyone who develops Alzheimer’s will have this allele.
- PSEN1, PSEN2, and APP genes: Mutations in the PSEN1, PSEN2, and APP genes are associated with early-onset familial Alzheimer’s disease, which is a rare form of the disease that typically occurs before the age of 65. Individuals with a family history of early-onset Alzheimer’s may undergo genetic testing for mutations in these genes to assess their risk.
Genetic testing for Alzheimer’s disease is not typically recommended for everyone. It is generally more helpful for individuals with a strong family history of the disease or those who are experiencing early-onset symptoms. Even if someone has a genetic risk factor, it does not guarantee that they will develop Alzheimer’s, as other factors such as lifestyle, environment, and complex interactions between genes and environment also play a significant role. “My duty is not only to offer the most comprehensive evaluation of the most difficult to treat patients, but also to connect these patients to the latest clinical trials and treatment modalities,” says neurologist Anna Szekely, MD from Yale Medical Group Neurology.
Genetic counseling is usually recommended before and after undergoing genetic testing for Alzheimer’s disease. This helps individuals understand the potential implications of their test results and make informed decisions about their health and future plans.
More information on Genetic Testing can be found here:
- Pharmacogenomics
- Carrier screening
- Gene Panels
Understanding the Differences: FDA-Approved At-Home Vs. Lab Testing for Alzheimer’s
FDA-Approved At-Home Test for Alzheimer’s Disease:
1. Accessibility and Convenience: An FDA-approved at-home test for Alzheimer’s disease provides the convenience of being able to take the test in the comfort of one’s own home.
2. Sample Collection: At-home tests often involve collecting a sample, such as a saliva sample or a cheek swab, as opposed to blood samples typically collected in a laboratory setting. This can be less invasive and more comfortable for individuals.
3. Testing Process: At-home tests usually involve following clear instructions provided by the testing kit. This can involve packaging and sending the sample back to the testing company for analysis.
4. Privacy and Control: At-home testing allows individuals to have more control over their testing process and potentially offers more privacy as compared to laboratory testing.
5. Timeliness: At-home tests may offer quicker results, as individuals can initiate the testing process as soon as they receive the kit.
Laboratory Testing for Alzheimer’s Disease:
1. Professional Oversight: Laboratory testing is typically conducted in a controlled medical environment under the supervision of trained healthcare professionals. This ensures accuracy and adherence to standardized procedures.
2. Variety of Tests: Laboratories offer a range of testing options, including genetic testing, brain imaging, cognitive assessments, and more. This diversity of tests allows for a comprehensive evaluation of Alzheimer’s risk and diagnosis from trained experts.
3. Complexity of Analysis: Laboratory tests, especially those involving genetic analysis, may require advanced equipment and expertise to accurately interpret results.
4. Clinical Context: Healthcare professionals in a laboratory setting can provide context to test results, taking into account an individual’s medical history, family history, and other relevant factors as is done at the National Institute for Aging.
5. Follow-Up Care: If test results indicate a higher risk or potential diagnosis of Alzheimer’s disease, a laboratory setting facilitates immediate access to medical advice and follow-up care such as the advice given by the Alzheimers Association.
It’s important to note that the choice between an FDA-approved at-home test and laboratory testing for Alzheimer’s disease depends on individual preferences, medical history, and the specific tests being considered.
The Future for Alzheimer’s Disease
Currently, over six million individuals in the United States are affected by Alzheimer’s disease, and this number is expected to increase to 13 million by the year 2050. This disease is also financially burdensome, with an estimated $321 billion in healthcare costs projected for the year 2022, and an anticipated rise to $1 trillion by 2050, according to an article published inalz.org. The future of Alzheimer’s disease prediction holds promise through advanced genetic testing, neuroimaging techniques, and biomarker discovery. Personalized risk assessments based on an individual’s genetic makeup and early biomarker detection may enable proactive interventions. Machine learning and AI could enhance predictive models, leading to more accurate risk stratification. Collaborative efforts in research and technology may ultimately contribute to earlier diagnosis and targeted interventions, improving the outlook for individuals at risk of Alzheimer’s disease.
Here is everything you need to know on Long-Read sequencing from A-Z
